In the SPOTLIGHT study, patients were defined as CLDN18.2‐positive if ≥ 75% of tumour cells showed moderate‐to‐strong membranous CLDN18 staining using the VENTANA® CLDN18 (43‐14A) RxDx assay. This evidence concerns the gene CLDN18 and neoplasm.